Pre-administration of BAX-inhibiting peptides decrease the loss of the nigral dopaminergic neurons in rats

Area of Science:

• Neuroscience
• Cell Biology
• Pharmacology

Background:

• Parkinson's disease (PD) is a neurodegenerative disorder characterized by the loss of dopaminergic neurons.
• 6-hydroxydopamine (6-OHDA) is commonly used to create an animal model of PD by inducing neuronal damage.
• Apoptosis, or programmed cell death, plays a critical role in the pathogenesis of PD.

Purpose of the Study:

• To investigate the neuroprotective effects of Bax-inhibiting peptide (Bip)-V5 in a 6-OHDA rat model of Parkinson's disease.
• To determine if Bip-V5 can prevent the loss of nigral dopaminergic neurons and reduce motor deficits induced by 6-OHDA.
• To elucidate the specific apoptosis pathways targeted by Bip-V5 in the context of PD.

Main Methods:

• Rats were induced with Parkinson's disease using 6-hydroxydopamine (6-OHDA).
• Different treatment groups received pre-administration of either Bip-V5, zVAD, or vehicle before 6-OHDA.
• Neuroprotection was assessed by measuring amphetamine-induced rotation, dopaminergic neuron survival, and the expression of apoptosis-related proteins (caspase 9, caspase 3, AIF).

Main Results:

• Bip-V5 treatment significantly reduced amphetamine-induced rotation in 6-OHDA rats.
• Intrastriatal pre-administration of Bip-V5 significantly decreased the loss of nigral dopaminergic neurons.
• Bip-V5 inhibited both caspase-dependent (caspase 9, caspase 3) and AIF-dependent apoptosis pathways.

Conclusions:

• The study provides the first experimental evidence that both caspase-dependent and AIF-dependent apoptosis pathways contribute to 6-OHDA-induced nigral dopaminergic neuron loss.
• Intrastriatal Bip-V5 administration effectively inhibits these apoptosis pathways, thereby protecting nigral dopaminergic neurons.
• Bax-inhibiting peptide (Bip)-V5 shows promise as a potential preventive or therapeutic agent for Parkinson's disease.